Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Legend Biotech Q3 2026 Results: Turns Profitable, Net Income $51.7M

Legend Biotech reported a significant turnaround for Q3 2026, achieving a net income of $51.7 million compared to a net loss of $39.6 million in the prior year, driven by higher CARVYKTI collaboration revenue and lower R&D and administrative expenses. Total revenue grew to $359.5 million, and the company achieved an operating income of $46.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue359.5272.4
Net income51.7-39.6

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+32.0%
Source

6-K filed with the SEC, NASDAQ: LEGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Legend Biotech Corp: key numbers

Share price
$15.99Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Legend Biotech Corp

All →
4:04 PM ET Form 4
Insider Selling

Legend Biotech Director Corazon (Corsee) D. Sanders Sells $259K of Stock

Corazon (Corsee) D. Sanders, Director, sold 27,370 shares of Legend Biotech Corp at $9.46 a share, worth $259K in total on Sep 29, 2026. Shares held after the trade: 52,731 (-34.2%).

Value
$259K
Shares
27,370
Price
$9.46
Role
Director
Holding change
-34.2%
Trade date
Sep 29, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.